Mohammad Taheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohammad Taheri has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Fatemeh Nouri
Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
14 shared publications - Seyed Mohammad Javad Mortazavi
Shiraz University of Medical Sciences
8 shared publications Fatemeh Nouri
Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran
6 shared publications- Mohammad Yousef Alikhani
Department of Medical Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
5 shared publications - Leili Shokoohizadeh
Infectious Disease Research Center, Avicenna Institute of Clinical Sciences, Avicenna Health Research Institute, Hamadan University of Medical Sciences, Hamadan, Iran
4 shared publications - Mohammad Moradi
Department of Microbiology and Virology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
4 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Springer Nature in International Microbiology
- p. 1-10
In vitro antibacterial and antibiofilm activity of phycocyanin against Klebsiella pneumoniae: effects on growth kinetics and antibiotic susceptibility
- 7 November 2026
- Published by Springer Nature in International Microbiology
- p. 1-10
Open AccessIn vitro antibacterial and antibiofilm activity of phycocyanin against Klebsiella pneumoniae: effects on growth kinetics and antibiotic susceptibility
- Open Access
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-16
Nanostructured Lipid Carriers Co-Loaded with Doxycycline, Gentamicin, and Thymol for Enhanced Intracellular Antibacterial Activity Against Brucella melitensis
Background: Brucellosis is a zoonotic infection caused by Brucella spp. which persist within macrophages and complicate treatment. This study developed nanostructured lipid carriers (NLCs) co-loaded with doxycycline, gentamicin, and thymol to enhance intracellular delivery and antibacterial activity against Brucella melitensis. Methods: Drug-loaded NLCs were prepared using high-shear homogenization followed by sonication. The formulations were characterized in terms of particle size, polydispersity index (PDI), zeta potential, morphology by FE-SEM, encapsulation efficiency, and in vitro drug release profile. Cytotoxicity was assessed using the MTT assay on J774A.1 macrophage. Antibacterial activity and intracellular efficacy against Brucella melitensis were evaluated using microbiological and cell-based assays. Results: The optimized formulation showed a size of 398 ± 30 nm, PDI 0.35, and zeta potential − 17.5 mV, with 97% encapsulation efficiency and stable morphology over nine months. The system exhibited sustained release up to 95% at 80 h, in contrast to rapid diffusion from free drugs. Intracellular studies showed that Gen–Dox–Thy@NLC achieved a 3.4-log reduction in bacterial load, demonstrating significantly higher efficacy (~1.6-log greater reduction) compared with free drugs (p < 0.05), while maintaining macrophage viability above 85%. Conclusion: The co-loaded NLC formulation provided controlled drug release, improved intracellular delivery, and enhanced antibacterial activity against Brucella melitensis. These findings suggest that Gen–Dox–Thy@NLC may serve as a promising candidate for brucellosis treatment and warrants further in vivo studies.
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-16
Open AccessNanostructured Lipid Carriers Co-Loaded with Doxycycline, Gentamicin, and Thymol for Enhanced Intracellular Antibacterial Activity Against Brucella melitensis
Background: Brucellosis is a zoonotic infection caused by Brucella spp. which persist within macrophages and complicate treatment. This study developed nanostructured lipid carriers (NLCs) co-loaded with doxycycline, gentamicin, and thymol to enhance intracellular delivery and antibacterial activity against Brucella melitensis. Methods: Drug-loaded NLCs were prepared using high-shear homogenization followed by sonication. The formulations were characterized in terms of particle size, polydispersity index (PDI), zeta potential, morphology by FE-SEM, encapsulation efficiency, and in vitro drug release profile. Cytotoxicity was assessed using the MTT assay on J774A.1 macrophage. Antibacterial activity and intracellular efficacy against Brucella melitensis were evaluated using microbiological and cell-based assays. Results: The optimized formulation showed a size of 398 ± 30 nm, PDI 0.35, and zeta potential − 17.5 mV, with 97% encapsulation efficiency and stable morphology over nine months. The system exhibited sustained release up to 95% at 80 h, in contrast to rapid diffusion from free drugs. Intracellular studies showed that Gen–Dox–Thy@NLC achieved a 3.4-log reduction in bacterial load, demonstrating significantly higher efficacy (~1.6-log greater reduction) compared with free drugs (p < 0.05), while maintaining macrophage viability above 85%. Conclusion: The co-loaded NLC formulation provided controlled drug release, improved intracellular delivery, and enhanced antibacterial activity against Brucella melitensis. These findings suggest that Gen–Dox–Thy@NLC may serve as a promising candidate for brucellosis treatment and warrants further in vivo studies.
- Open Access
- 9 February 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26  (1)
Genetic diversity, antimicrobial resistance, and biofilm-associated virulence in clinical Enterococcus faecalis isolates from Hamedan, Iran
Enterococcus faecalis is a leading cause of hospital-acquired infections, exhibiting high-level antimicrobial resistance, robust biofilm-forming capacity,
- 9 February 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26  (1)
Open AccessGenetic diversity, antimicrobial resistance, and biofilm-associated virulence in clinical Enterococcus faecalis isolates from Hamedan, Iran
Enterococcus faecalis is a leading cause of hospital-acquired infections, exhibiting high-level antimicrobial resistance, robust biofilm-forming capacity,
- Open Access
- 7 January 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30  (1) , 1-17
Natural products in the treatment of diabetic foot infection
Diabetic foot infections (DFIs) are a significant complication in diabetes mellitus, leading to increased morbidity, hospitalizations, and healthcare burdens. The growing prevalence of antibiotic-resistant pathogens has reduced the efficacy of conventional treatments, highlighting the need for alternative therapeutic strategies. Natural products, known for their antimicrobial, anti-inflammatory, and wound-healing properties, have garnered attention as potential treatments for DFIs. This review examines key natural compounds, including eugenol, thymol, carvacrol, curcumin, and Aloe vera, and their mechanisms of action in combating diabetic infections. We analyze the antimicrobial efficacy of these compounds, their ability to inhibit biofilm formation, and their role in wound healing. The review also explores challenges in integrating natural products into clinical practice and the potential for their use alongside or in place of traditional antibiotic therapies. Our findings suggest that natural products could play a crucial role in developing sustainable and effective treatment strategies for DFIs, especially in the face of rising antimicrobial resistance.
- 7 January 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30  (1) , 1-17
Open AccessNatural products in the treatment of diabetic foot infection
Diabetic foot infections (DFIs) are a significant complication in diabetes mellitus, leading to increased morbidity, hospitalizations, and healthcare burdens. The growing prevalence of antibiotic-resistant pathogens has reduced the efficacy of conventional treatments, highlighting the need for alternative therapeutic strategies. Natural products, known for their antimicrobial, anti-inflammatory, and wound-healing properties, have garnered attention as potential treatments for DFIs. This review examines key natural compounds, including eugenol, thymol, carvacrol, curcumin, and Aloe vera, and their mechanisms of action in combating diabetic infections. We analyze the antimicrobial efficacy of these compounds, their ability to inhibit biofilm formation, and their role in wound healing. The review also explores challenges in integrating natural products into clinical practice and the potential for their use alongside or in place of traditional antibiotic therapies. Our findings suggest that natural products could play a crucial role in developing sustainable and effective treatment strategies for DFIs, especially in the face of rising antimicrobial resistance.
- Open Access
- 27 August 2024
- Published by Qeios Ltd
Review of: "A Review of the Scientific Literature on Experimental Toxicity Studies of COVID-19 Vaccines, with Special Attention to Publications in Specific Toxicology Journals"
Dear Editor, Expanding the scope of the search to include a broader range of journals could have yielded a more comprehensive set of data and insights. The article provides an overview of the findings from the reviewed studies but lacks a deeper, cr...
- 27 August 2024
- Published by Qeios Ltd
Open AccessReview of: "A Review of the Scientific Literature on Experimental Toxicity Studies of COVID-19 Vaccines, with Special Attention to Publications in Specific Toxicology Journals"
Dear Editor, Expanding the scope of the search to include a broader range of journals could have yielded a more comprehensive set of data and insights. The article provides an overview of the findings from the reviewed studies but lacks a deeper, cr...
- Open Access
- 16 July 2024
- Published by Frontiers Media SA in Frontiers: A Journal of Women Studies
- Vol. 4, 1405680
Investigation of COVID-19 virus mutagenicity and the effect of the NSP13, NSP14, and NSP16 on the -1 ribosomal frameshifting
The COVID-19 virus is a single-stranded virus from the Coronaviridae family and has a genome of about 29881 bp, which causes acute respiratory disease. One way of transmission of the COVID-19 virus is respiratory, which is the reason for the significant transmission of the disease. The COVID-19 virus causes mutagenesis in different parts of the virus genome with its mechanisms, including -1 ribosomal frameshifting. Various parts that have undergone the most severe mutations include the spike protein, which leads to the emergence of new variants. Most of the mutations observed in the COVID-19 virus are located in the S protein and a region known as the RBD (Receptor-Binding Domain), which binds to the ACE2 (Angiotensin-converting enzyme 2) receptor in human cells. The variations in the RBD region will determine how it binds to the ACE2 receptor. Essentially, the changes created because of the mutation determine the affinity of the RBD to ACE2. On the other hand, the COVID-19 virus, because of its NSP13, NSP14, and NSP16 proteins, helps the mutation of the virus by consuming magnesium ions (Mg2+). Since the ribosome is stable with Mg2+, the COVID-19 virus, by consuming Mg2+, causes the ribosome to convert from the polysome to the monosome state, which causes a break in translation and finally leads to the formation of -1 ribosomal frameshifting.
- 16 July 2024
- Published by Frontiers Media SA in Frontiers: A Journal of Women Studies
- Vol. 4, 1405680
Open AccessInvestigation of COVID-19 virus mutagenicity and the effect of the NSP13, NSP14, and NSP16 on the -1 ribosomal frameshifting
The COVID-19 virus is a single-stranded virus from the Coronaviridae family and has a genome of about 29881 bp, which causes acute respiratory disease. One way of transmission of the COVID-19 virus is respiratory, which is the reason for the significant transmission of the disease. The COVID-19 virus causes mutagenesis in different parts of the virus genome with its mechanisms, including -1 ribosomal frameshifting. Various parts that have undergone the most severe mutations include the spike protein, which leads to the emergence of new variants. Most of the mutations observed in the COVID-19 virus are located in the S protein and a region known as the RBD (Receptor-Binding Domain), which binds to the ACE2 (Angiotensin-converting enzyme 2) receptor in human cells. The variations in the RBD region will determine how it binds to the ACE2 receptor. Essentially, the changes created because of the mutation determine the affinity of the RBD to ACE2. On the other hand, the COVID-19 virus, because of its NSP13, NSP14, and NSP16 proteins, helps the mutation of the virus by consuming magnesium ions (Mg2+). Since the ribosome is stable with Mg2+, the COVID-19 virus, by consuming Mg2+, causes the ribosome to convert from the polysome to the monosome state, which causes a break in translation and finally leads to the formation of -1 ribosomal frameshifting.
- Open Access
- 31 May 2024
- Published by Qeios Ltd
Review of: "Effects of Cinnamon on Cancer Prevention and Progression"
In summary, the article underscores the potential of cinnamon in cancer prevention and treatment, underscoring the importance of further research to confirm its effectiveness and safety. Areas for future research include studying miRNA effects, enhan...
- 31 May 2024
- Published by Qeios Ltd
Open AccessReview of: "Effects of Cinnamon on Cancer Prevention and Progression"
In summary, the article underscores the potential of cinnamon in cancer prevention and treatment, underscoring the importance of further research to confirm its effectiveness and safety. Areas for future research include studying miRNA effects, enhan...
- Open Access
- 15 May 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18  (1) , 1-13
Co-delivery of doxycycline and rifampicin using CdTe-labeled poly (lactic-co-glycolic) acid for treatment of Brucella melitensis infection
Brucellosis poses a significant challenge in the medical field as a systemic infection with a propensity for relapse. This study presented a novel approach to brucellosis treatment, enhancing the efficacy of doxycycline and rifampicin through the use of poly (lactic-co-glycolic) acid coupled with cadmium-telluride quantum dots (Dox-Rif-PLGA@CdTe). The double emulsion solvent evaporation method was employed to prepare Dox-Rif-PLGA@CdTe. The study scrutinized the physicochemical attributes of these nanoparticles. The impact of antibiotic-loaded nanoparticles on Brucella melitensis was evaluated through well diffusion, minimum inhibitory concentration (MIC), and cell culture. The chemical analysis results demonstrated a possibility of chemical reactions occurring among the constituents of nanoparticles. Assessments using the well diffusion and MIC methods indicated that the impact of free drugs and nanoparticles on bacteria was equivalent. However, the drug-loaded nanoparticles significantly decreased the colony-forming units (CFUs) within the cell lines compared to free drugs. In conclusion, the synthesis of nanoparticles adhered to environmentally friendly practices and demonstrated safety. The sustained drug release over 100 h facilitated drug accumulation at the bacterial site, resulting in a heightened therapeutic effect on B. melitensis and improved outcomes in brucellosis treatment. The application of these synthesized nanodrugs exhibited promising therapeutic potential.
- 15 May 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18  (1) , 1-13
Open AccessCo-delivery of doxycycline and rifampicin using CdTe-labeled poly (lactic-co-glycolic) acid for treatment of Brucella melitensis infection
Brucellosis poses a significant challenge in the medical field as a systemic infection with a propensity for relapse. This study presented a novel approach to brucellosis treatment, enhancing the efficacy of doxycycline and rifampicin through the use of poly (lactic-co-glycolic) acid coupled with cadmium-telluride quantum dots (Dox-Rif-PLGA@CdTe). The double emulsion solvent evaporation method was employed to prepare Dox-Rif-PLGA@CdTe. The study scrutinized the physicochemical attributes of these nanoparticles. The impact of antibiotic-loaded nanoparticles on Brucella melitensis was evaluated through well diffusion, minimum inhibitory concentration (MIC), and cell culture. The chemical analysis results demonstrated a possibility of chemical reactions occurring among the constituents of nanoparticles. Assessments using the well diffusion and MIC methods indicated that the impact of free drugs and nanoparticles on bacteria was equivalent. However, the drug-loaded nanoparticles significantly decreased the colony-forming units (CFUs) within the cell lines compared to free drugs. In conclusion, the synthesis of nanoparticles adhered to environmentally friendly practices and demonstrated safety. The sustained drug release over 100 h facilitated drug accumulation at the bacterial site, resulting in a heightened therapeutic effect on B. melitensis and improved outcomes in brucellosis treatment. The application of these synthesized nanodrugs exhibited promising therapeutic potential.
- 1 December 2023
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 13  (6) , 351-369
A Review on Nonviral, Nonbacterial Infectious Agents Toxicity Involved in Neurodegenerative Diseases
Neuronal death, decreased activity or dysfunction of neurotransmitters are some of the pathophysiological reasons for neurodegenerative diseases like Alzheimer's, Parkinson's and multiple sclerosis...
- 1 December 2023
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 13  (6) , 351-369
A Review on Nonviral, Nonbacterial Infectious Agents Toxicity Involved in Neurodegenerative Diseases
Neuronal death, decreased activity or dysfunction of neurotransmitters are some of the pathophysiological reasons for neurodegenerative diseases like Alzheimer's, Parkinson's and multiple sclerosis...
- 2 November 2023
- Published by Taylor & Francis in Journal of Essential Oil Research
- Vol. 35  (6) , 570-578
Evaluation of thymol effect on antimicrobial susceptibility and biofilm production in clinical Enterobacter spp . producing ESBLs and KPC enzymes
- 2 November 2023
- Published by Taylor & Francis in Journal of Essential Oil Research
- Vol. 35  (6) , 570-578
Evaluation of thymol effect on antimicrobial susceptibility and biofilm production in clinical Enterobacter spp . producing ESBLs and KPC enzymes